Design and Synthesis of a Peptide-Based Glioma-Targeted Drug Delivery Vector gHope2
© 2021. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature..
In the current chapter, we are detailing the synthesis path of a tumor-targeted, CPP-functionalized chemotherapeutic drug, as well as in vitro validation of the targeting and cell penetrating functionalities of the construct. The design of targeted drug delivery vehicle is based on a new glioma-specific homing peptide that has been conjugated to doxorubicin. Further functionalization with an 18-amino acid cell penetrating peptide pVEC was achieved, a CPP that was chosen because of its high cell penetrating efficacy and low toxicity. The three elements were combined into one drug delivery construct gHope2, and its tumor-homing and cell penetrating activity was demonstrated in human glioma cell line U87.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2355 |
|---|---|
| Enthalten in: |
Methods in molecular biology (Clifton, N.J.) - 2355(2021) vom: 12., Seite 117-129 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kurrikoff, Kaido [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CPP |
|---|
| Anmerkungen: |
Date Completed 11.01.2022 Date Revised 11.01.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1007/978-1-0716-1617-8_11 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32930738X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32930738X | ||
| 003 | DE-627 | ||
| 005 | 20231225204830.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/978-1-0716-1617-8_11 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1097.xml |
| 035 | |a (DE-627)NLM32930738X | ||
| 035 | |a (NLM)34386955 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kurrikoff, Kaido |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Design and Synthesis of a Peptide-Based Glioma-Targeted Drug Delivery Vector gHope2 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.01.2022 | ||
| 500 | |a Date Revised 11.01.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a In the current chapter, we are detailing the synthesis path of a tumor-targeted, CPP-functionalized chemotherapeutic drug, as well as in vitro validation of the targeting and cell penetrating functionalities of the construct. The design of targeted drug delivery vehicle is based on a new glioma-specific homing peptide that has been conjugated to doxorubicin. Further functionalization with an 18-amino acid cell penetrating peptide pVEC was achieved, a CPP that was chosen because of its high cell penetrating efficacy and low toxicity. The three elements were combined into one drug delivery construct gHope2, and its tumor-homing and cell penetrating activity was demonstrated in human glioma cell line U87 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a CPP | |
| 650 | 4 | |a Cancer targeting | |
| 650 | 4 | |a Cell-penetrating peptides | |
| 650 | 4 | |a Chemical conjugate | |
| 650 | 4 | |a Doxorubicin | |
| 650 | 4 | |a Glioma | |
| 650 | 7 | |a Cell-Penetrating Peptides |2 NLM | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 700 | 1 | |a Oskolkov, Nikita |e verfasserin |4 aut | |
| 700 | 1 | |a Eriste, Elo |e verfasserin |4 aut | |
| 700 | 1 | |a Langel, Ülo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Methods in molecular biology (Clifton, N.J.) |d 1984 |g 2355(2021) vom: 12., Seite 117-129 |w (DE-627)NLM074849794 |x 1940-6029 |7 nnns |
| 773 | 1 | 8 | |g volume:2355 |g year:2021 |g day:12 |g pages:117-129 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/978-1-0716-1617-8_11 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 2355 |j 2021 |b 12 |h 117-129 | ||